Women who have been newly diagnosed with advanced high grade ovarian cancer and who have either undergone upfront primary surgery or plan to start chemotherapy followed by interval debulking surgery may be eligible to participate in this study. This treatment, which will consist of 2 independent cohorts, will evaluate the efficacy and safety of durvalumb and olaparib when added to standard of care. This study isled by Dr. Gottfried Konecny and his research team from the UCLA Department of Obstetrics and Gynecology.
Participants must meet the following criteria:
Plan to undergo chemotherapy with interval debulking surgery
If you've answered yes to all of the above questions, please
Email: email@example.com or Call: 310-267-4331.
Participants will be allocated to two cohorts:
All participants enrolled in the study will undergo the following testing:
Once in the study, participants will be randomized (like drawing numbers from a hat) to one of the treatment groups. As this is a placebo-controlled study, please note that you may receive inactive medications.
UCLA Protocol ID: IRB# 18-001944.
Please call (310) 267-4331 to learn more. In order to protect your privacy, please do not include any personal health information if you choose to e-mail us.